Improved glycemic and weight control with Dulaglutide addition in SGLT2 inhibitor treated obese type 2 diabetic patients at high cardiovascular risk in a real-world setting. The AWARE−2 study

Improved glycemic and weight control with Dulaglutide addition in SGLT2 inhibitor treated obese type 2 diabetic patients at high cardiovascular risk in a real-world setting. The AWARE−2 study

We evaluated the effects on glycemic control and body weight of a GLP1-RA in obese type 2 diabetic patients treated with SGLT2-inhibitors and other hypoglycemic agents and/or insulin, in a real-world setting. A cohort of 583 type 2 diabetic outpatients treated with a SGLT2 inhibitor and/or other ant...

Full description

Saved in:
Bibliographic Details
Main Authors: Cesare Berra, Roberto Manfrini, Francesco Bifari, Elisa Cipponeri, Renata Ghelardi, Lucia Centofanti, Umberto Mortola, Elena Lunati, Loredana Bucciarelli, Vincenzo Cimino, Franco Folli
Format: Article
Language:English
Published: Elsevier 2024-12-01
Series:Pharmacological Research
Subjects:
Type 2 Diabetes Mellitus
Cardiovascular risk
AWARE app
Glucagon Like Peptide 1 Receptor Agonists
Sodium-Glucose Co-Transporter-2 inhibitors
Online Access:http://www.sciencedirect.com/science/article/pii/S1043661824004626
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://www.sciencedirect.com/science/article/pii/S1043661824004626

Similar Items